Minimal residual disease assessment
We are always on the lookout for collaborators.
Academic research, start-up or pharmaceutical industry. If you are excited about blood-based cancer genomics or highly sensitive minimal residual disease assessment across cancers we should start a conversation.
Get in contact with us and let us explore how we can team up.
